This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2004 in patients with advanced tumors.
Participant must be ≥ 18 years of age.
Histologically or cytologically confirmed diagnosis of locally advanced or metastatic malignancy.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
All participants should have at least 1 measurable site of disease according to RECIST v1.1. An irradiated lesion can be considered measurable only if progression has been demonstrated on the irradiated lesion.
Any clinically significant cardiac disease.
Unresolved toxicities from previous anticancer therapy.
Known untreated, active, or uncontrolled brain metastases.
Previous Grade 3 or 4 immune-related toxicity that led to the discontinuation of treatment, within 6 months prior to the first dose of MDX2004.